CMBT vs TRMD

CMBT presents a contradictory profile: explosive revenue growth (160% YoY) paired with a deteriorating earnings track record and poor liquidity. While the Piotroski F-Score of 6/9 indicates stable financial health, the company has missed earnings estimates in 4 consecutive quarters with a severe average surprise of -156.54%. The stock trades slightly above its Graham Number ($11.93) and significantly above its growth-based intrinsic value ($4.90), suggesting a valuation premium that is not currently supported by bottom-line performance. High leverage (Debt/Equity 2.12) and a current ratio below 1.0 create a precarious financial position despite strong operating margins.

TRMD presents a compelling value opportunity, trading significantly below both its Graham Number ($37.33) and Intrinsic Value ($64.41). While the Piotroski F-Score of 4/9 indicates only stable financial health, the company's profitability metrics (21.3% profit margin) and low Debt/Equity (0.46) far outperform sector averages. Despite a starkly bearish technical trend (10/100) and weak insider sentiment, the fundamental valuation and strong dividend yield provide a significant margin of safety.